Rankings
▼
Calendar
JAZZ Q3 2023 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena
JAZZ
Jazz Pharmaceuticals plc
$12B
Q3 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$972M
+3.3% YoY
Gross Profit
$870M
89.5% margin
Operating Income
$172M
17.7% margin
Net Income
$147M
15.1% margin
EPS (Diluted)
$2.14
QoQ Revenue Growth
+1.5%
Cash Flow
Operating Cash Flow
$307M
Free Cash Flow
$303M
Stock-Based Comp.
$56M
Balance Sheet
Total Assets
$11.2B
Total Liabilities
$7.7B
Stockholders' Equity
$3.5B
Cash & Equivalents
$1.3B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$972M
$941M
+3.3%
Gross Profit
$870M
$807M
+7.8%
Operating Income
$172M
$25M
+596.2%
Net Income
$147M
-$20M
+847.3%
Revenue Segments
Xywav
$332M
34%
Epidiolex/Epidyolex
$214M
22%
Xyrem
$125M
13%
Rylaze/Enrylaze
$105M
11%
Zepzelca
$78M
8%
Defitelio/Defibrotide
$48M
5%
Vyxeos
$30M
3%
High Sodium AG Oxybate Product Royalty Revenue
$29M
3%
Other Royalty And Contract Revenues
$5M
0%
Sativex
$5M
0%
Other Products
$3M
0%
Geographic Segments
UNITED STATES
$885M
91%
Europe
$69M
7%
Other Countries
$19M
2%
← FY 2023
All Quarters
Q4 2023 →